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ABSTRACT
Regulation of gene expression represents a central
issue in signal-regulated cellular responses. STAT6
is a critical mediator of IL-4 stimulated gene acti-
vation. To mediate this function, STAT6 recruits
co-activator complexes. We have previously shown
that STAT6 binds the PAS-B domain of the
co-activator NCoA-1 via an LXXLL motif in its trans-
activation domain. Our recent finding that the PAS-B
domain of NCoA-1 is also essential for co-activator
complex formation points to an additional level
of regulation of the co-activator assembly. In this
study, we discovered that dephosphorylation of
NCoA-1 is essential for the interaction with STAT6
and for IL-4-dependent transcriptional activation.
PP2A dephosphorylates NCoA-1 and facilitates
the activation of STAT6 target genes. Interestingly,
simultaneous inhibition of phosphatase and cyclin-
dependent kinases rescues the NCoA-1/STAT6
interaction. Moreover, arrest of cells at G1/S
results in enhanced NCoA-1 phosphorylation. In
summary, our results indicate that the interaction
of NCoA-1 and STAT6 is dynamically regulated by
the phosphatase PP2A and by cyclin-dependent
kinases. This provides a mechanism for integrating
transcriptional regulation by STAT6 with cell cycle
progression.
INTRODUCTION
Interleukin-4 (IL-4) is a pleiotropic cytokine which regu-
lates differentiation, proliferation and survival in a variety
of cell types most notably in lymphocytes (1). Aberrant
activation of IL-4 signaling is frequently associated with
pathogenesis of leukaemia and lymphoma cells (2). IL-4
exerts its function mainly through activation of STAT6.
IL-4 binding to its receptor results in phosphorylation of
a speciﬁc tyrosine residue in STAT6 via Janus kinases.
Phosphorylated STAT6 dimers bind to speciﬁc response
elements in the promoter of IL-4 responsive genes and
induce the assembly of the transcriptional machinery via
the recruitment of speciﬁc co-activators (3).
Co-activators are essential for the transactivation po-
tential of transcription factors and mediate the speciﬁcity
for the promoters which are activated (4). The recruitment
of transcriptional co-activators to target gene promoters
and enhancers is a highly dynamic, sequential and ordered
process (5). Co-activators function in multiprotein
complexes which act as bridging factors to the general
transcription machinery and modify histones to open the
chromatin structure of the promoters. They possess struc-
tural domains, which provide surfaces for interactions
with DNA-bound transcription factors and with other
components of the multiprotein complexes. The p160/
SRC/NCoA co-activator family contains three homolo-
gous members (6). They were ﬁrst identiﬁed as transcrip-
tional co-activators of nuclear receptors and subsequently
found to be involved in transcriptional activation of sev-
eral different transcription factors, like members of
the STAT family (7–9) or NFkB (10,11). NCoA proteins
are part of multiprotein complexes which contain
co-activators with histone acetyltransferase activity
(HAT), like NCoA-1, NCoA-3, p300, CBP and p/CAF
and cofactors with histone methyltransferase activity
(HMT), like CARM1 and PRMT1 (12). NCoA proteins
also contain speciﬁc LXXLL motifs which mediate the
interaction with nuclear receptors via the nuclear
receptor interaction domain (NID), as well as with p300/
CBP through the so called CBP-interaction domain
(CID), also called activation domain (AD1).
In previous studies, we found that NCoA-1 is recruited
by the IL-4 activated transcription factor STAT6 (7).
STAT6 directly contacts the PAS (Per/ARNT/Sim)
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leucine and X is any amino acid) in its transactivation
domain (7). The crystal structure of the NCoA-1 PAS-B
domain in complex with the STAT6 LXXLL motif
revealed that speciﬁc surface complementarities between
the hydrophobic faces of the STAT6 LXXLL motif and
of the NCoA-1 PAS-B domain almost exclusively deﬁne
the binding speciﬁcity (13). Further characterization of the
binding speciﬁcity revealed that the PAS-B domain is able
to recognize the LXXLL motifs in its own CID/AD1
domain and also the LXXLL motifs in the CID/AD1
domain of NCoA-3 (14). Moreover, we demonstrate
that the STAT6 and CID/AD1 motifs can compete for
binding to the PAS-B domain. These ﬁndings indicate
that the different interactions of NCoA-1 with STAT6,
CBP and other NCoA family members are most likely
dynamically regulated during the transcriptional activa-
tion process.
Several studies indicate that NCoA proteins are
modiﬁed by post-translational modiﬁcations like phos-
phorylation, sumoylation, ubiquitination and methylation
(15). Post-translational modiﬁcations may induce con-
formational changes and thereby inﬂuence the different
interaction possibilities of co-activators (16). Induced
post-translational modiﬁcation thus lead to the integra-
tion of different signals in cellular transcriptional
response (17).
IL-4 induced transcriptional activation by STAT6
involves multiple serine/threonine kinase pathways
in addition to tyrosine phosphorylation (18–20). STAT6
was shown to be phosphorylated on serine residues in
response to IL-4 stimulation (21,22). Although the phos-
phorylation sites of STAT6 are mapped mainly to its
transactivation domain, the role of the serine phosphoryl-
ation is still unclear. Both positive and negative effects on
the transcriptional activation have been described (21,22).
An implication of protein phosphatases in the regulation
of STAT6 serine phosphorylation has also been described
(23). All these studies do not address the effect of serine/
threonine kinase and phosphatase pathways on the
STAT6/coactivator assembly. In this study, we analyze
how complex formation of STAT6 with its co-activator
NCoA-1 is affected by phosphorylation pathways. We
report here that the phosphorylation state of NCoA-1
but not that of STAT6 is essential for their interaction.
NCoA-1 is dephosphorylated by PP2A. PP2A enhances
the transcriptional activation by STAT6 and is essential
for the expression of IL-4 induced target genes. Combined
inhibitor treatment experiments indicate that phosphoryl-
ation of NCoA-1 by cell cycle regulated kinases and
dephosphorylation by PP2A regulate its interaction poten-
tial with STAT6.
MATERIALS AND METHODS
Cell culture, transient transfection and metabolic
labeling
293T cells were grown in Dulbeccos minimal essential
medium (DMEM) containing 10% fetal calf serum.
A549, BJAB, Ramos and THP-1 cells were cultured in
RPMI 1640 medium supplemented with 10% fetal calf
serum. 293T cells were transiently transfected using
polyethylenimin. siRNA (10nM) was transfected in
293T cells by using SilentFect reagent (Bio-Rad). For
transfection of Ramos with siRNA (40nM) cells were
electroporated using the Gene Pulser Xcell electroporation
system (Bio-Rad). Analysis was performed 48h after
transfection. Cells were starved in medium containing
1% fetal calf serum 24h before IL-4 stimulation
(10ng/ml). For stimulation with 17b-estradiol (E2,
10
 7M), cells were grown in phenol red-free medium sup-
plemented with 10% charcoal-dextran-stripped fetal calf
serum for 2 days prior to treatment. For the P
32 metabolic
labeling 293T cells were seeded at 30% conﬂuency. They
were transiently transfected with 1.5mg of NCoA-1 ex-
pression vector 24h later. Another day later, they were
washed twice with PBS followed by a 2-h incubation in
phosphate-free medium. After renewal of the media,
0.1mCi P
32 were added per 6cm dish. Two hours later,
IL-4 and inhibitors were added as indicated for another
2h. For the metabolic labeling of BJAB cells, 2 10
7 cells
were washed in phosphate-free medium and incubated in
phosphate-free medium for 2h. After renewal of the
medium, 0.5mCi P
32 were added per sample and 2h
later IL-4 and inhibitors were added as indicated. After
cell lysis STAT6 and NCoA-1 were precipitated and
analyzed by SDS–PAGE and autoradiography.
Recombinant plasmids, constructs and siRNA
The GST fusion constructs containing different fragments
with amino acids numbers given are constructed or
derived as described. The GST-STAT6 TAD fusion con-
struct (642–847) was constructed by cloning the PCR
ampliﬁed fragment in frame in the pGEX-2T vector.
GST fusion constructs containing the estrogen receptor
activation domain (312–595) was constructed by cloning
the cDNA Fragment in frame in the pGEX-2T vector.
pGEX-expression vector containing the hNCoA-1
fragment (260–370) has been described earlier (14). GST
fusion constructs containing the PP2A A protein and C
fragment were derived from Richard Karas, Boston and
has been described (24). The expression vector for human
estrogen receptor (pRSV-hER) and the LacZ expression
plasmid (pCH110) were used previously (14). Expression
vectors for hNCoA-1 (pSG-SRC-1e), were provided
by J. Torchia, and have been described previously (7).
The expression plasmid for STAT6, pSG6 STAT6 was
used previously (8). The expression plasmid for
HA-PP2A was obtained from Markus Heim, Basel and
was described (25).
The STAT6 reporter plasmid N4(STAT6-RE)3
LUC was described before (7). The estrogen responsive
element (ERE) luciferase reporter construct (pGL2-ERE
TK-luc) was obtained from L. Klein-Hitpass and has been
described previously (14).
Twenty-seven-mer siRNAs targeting PP2A were pur-
chased from Integrated DNA Technologies (Coralville).
Sequences are available upon request.
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Co-immunoprecipitation and western blotting of en-
dogenous proteins from Ramos or BJAB cells and
proteins from transiently transfected 293T cells was
performed as described previously (7). Nuclear and
cytoplamic fractionation was performed as described in
(26). Antibodies against the following different antigens
were used: GFP (Clontech), SRC-1 (M341, Santa Cruz),
SRC-1 (1135, Santa Cruz), SRC-2 (OBT1796, AbD
Serotec), NCoA-3 (M397, Santa Cruz), PP2A (clone
1D6, Upstate), STAT6 (M20 for IP, M200 for Co-IP,
Santa Cruz), STAT6 (clone 23, Transduction
Laboratories), Phospho-STAT6 (9361, Cell Signaling),
unspeciﬁc IgG (Santa Cruz), Sin3a (K20, Santa Cruz)
and Tubulin (Clone B-5-1-2, Sigma). Visualization was
performed with the ECL western blotting Detection
System (Pierce).
GST pull-down experiments
For GST pull-down experiments, 5mg of GST or GST-
fusion protein coupled to glutathione sepharose beads
were used. Of extracts, 200–1000mg from cells treated
with the inhibitors as indicated, were incubated with
the coupled GST-fusion proteins over night in NETN
buffer (20mM Tris–HCL pH 8, 100mM NaCl, 1mM
EDTA, 0.2% NP-40, 10% Glycerin with complete
protease inhibitors from Roche and phosphatase
inhibitors from Sigma). The amount and integrity of
bound GST proteins was controlled after SDS–PAGE in
each experiment by Coomassie blue staining. The binding
of the interacting proteins was detected by western
blotting.
Phosphatase assays
The phosphatase activity in cell extracts prepared in
NETN-Buffer without EDTA and phosphatase inhibitors
was analyzed in a 96-well plates with 10ml of lysate and
40ml incubation buffer (100mM Hepes pH 7.5, 150mM
NaCl, 12.5mM pNPP, 1mM DTT, protease inhibitor
complete from Roche). After 30min incubation at 37 C,
the reaction was stopped by addition of 50ml of 1N NaOH
and the absorption was determined at 405nm.
Luciferase assays
293T cells were seeded in 24-well plates and 1day after,
transiently transfected with siRNAs or expression vectors.
STAT6 reporter plasmid 100ng or 500ng ER reporter
plasmid, 50ng STAT6 expression plasmid or 5ng
estrogen receptor expression plasmid, 5ng LacZ expres-
sion plasmid for normalization and 10ng GFP expression
plasmid were transfected. The total amount of DNA was
adjusted with the corresponding empty vector. The cells
were stimulated with IL-4 (10ng/ml) 16 h later for 10h or
24h later with 10
 7M1 7 b-estradiol (E2) for 16h. The
cells were harvested and luciferase and b-galactosidase
activities were assayed. Luciferase activities were
normalized to the LacZ expression. The average of three
independent experiments with standard deviation is
shown.
Preparation of RNA and real time-PCR
Extraction of total cellular RNA and cDNA synthesis was
performed as described earlier with the modiﬁcation that
the RevertAid
TM First Strand cDNA Synthesis Kit
(Fermentas) was used (14). For quantiﬁcation of speciﬁc
transcripts, the i-Cycler MyiQ Single Color Real-Time
PCR Detection System (Bio-Rad) was used.
Ampliﬁcation of samples was performed in triplicates.
mRNA levels were normalized against endogenous 18S
RNA. The following primers for the speciﬁc ampliﬁcation
of the transcripts were used: 18S RNA: 50-CGGCTACCA
CATCCAAGGA-30;5 0-CCAATTACAGGGCCTCGA
AA-30 (27); Ig-epsilon 50-CACATCCACAGG CACCAA
AT-30;5 0-ATCACCGGCTCCGGGAAGTA-30; TARC
50-CCAGGGATGCCATCGTTTTTGTAACTGTGC-30;
50-CCTCACTGTGGCTCTTCTTCGTCCCTGGAA-30.
Electrophoretic mobility-shift assay
293T cells, which do not contain functional STAT6 were
transiently transfected with STAT6 expression plasmid
(2mg/10-cm dish). The cells were stimulated after 24h
post-transfection with IL-4 (10ng/ml) in the presence of
different concentrations of calyculin A for 30min.
Preparation of whole-cell extracts and mobility-shift
assay was performed as described before (8).
RESULTS
Phosphatases are essential for the regulation of the
STAT6 and NCoA-1 interaction
Previous studies demonstrate that serine/threonine kinases
inﬂuence transcriptional activation by STAT6 (18,20). In
addition, the phosphatase PP2A has been described to
regulate IL-4-mediated STAT6 signaling (23). In order
to investigate whether serine/threonine phosphorylation
affects the interaction of STAT6 with its co-activator
NCoA-1, co-immunoprecipitation experiments were per-
formed in 293T cells treated with inhibitors speciﬁc for
serine/thronine kinases and phosphatases known to be
involved in transcriptional regulation by IL-4. NCoA-1
was coprecipitated with GFP tagged STAT6 but not
with the control antibodies (IgG) conﬁrming complex for-
mation of the proteins (Figure 1, left panel). The inter-
action was not enhanced by IL-4 treatment of the cells
as shown in previous studies (7), (8). Treatment of
the cells with kinase inhibitors did not affect the
STAT6/NCoA-1 interaction. Only calyculin A is a PP1/
PP2A phosphatase inhibitor abrogated the STAT6/
NCoA-1 interaction. Immunoprecipitation of GFP-
STAT6 protein was not affected by inhibitor treatment
(Figure 1, right panel). These experiments clearly demon-
strate that phosphatases regulate the STAT6/NCoA-1
complex formation.
Both STAT6 and NCoA-1 are modiﬁed by phosphatases
We next investigated whether inhibition of phosphatases
results in a modiﬁcation of STAT6 and NCoA-1. For this,
we treated various IL-4 responsive cell lines with different
concentrations of the phosphatase inhibitors okadaic
Nucleic Acids Research,2011, Vol.39, No. 8 3257acid and calyculin A. The electrophoretic mobility of en-
dogenous STAT6 and NCoA-1 was analyzed by western
blotting with speciﬁc antibodies. The mobility of both
STAT6 and NCoA-1 was retarded in A549 cells treated
with either of the phosphatase inhibitors (Figure 2A).
Similar results were observed in the cell lines Ramos B
and THP-1. These results indicate that not only STAT6
(23), but also NCoA-1 is modiﬁed by phosphatases. The
degree of modiﬁcation varied between the analyzed cell
lines and phosphatase inhibitors as estimated by the
mobility shift of the proteins and obviously depends on
kinase pathways, which are currently active in the differ-
ent cell lines.
In order to conﬁrm that phosphatase inhibitor treat-
ment of cells promotes the phosphorylation of STAT6
and NCoA-1, we conducted metabolic labeling experi-
ments with radioactive P
32-ATP. These experiments were
performed in BJAB cells which contain a high amount of
NCoA-1. Cells were treated with IL-4, calyculin A or with
calyculin A in the presence of IL-4 or the broad-spectrum
kinase inhibitor staurosporine during labeling to ﬁnd out
whether the phosphorylation is inducible and reversible.
STAT6 and NCoA-1 were precipitated from cell lysates
and subsequently analyzed by SDS–PAGE and autoradi-
ography (Figure 2B).
Calyculin A treatment caused a stronger phosphoryl-
ation of both STAT6 and NCoA-1. IL-4 treatment
moderatly enhanced the phosphorylation level of
STAT6, but not that of NCoA-1. Cotreatment of the
cells with the phosphatase inhibitor calyculin A and the
kinase inhibitor staurosporine prevented the phosphoryl-
ation of both proteins. Thus these results conﬁrmed that
both STAT6 and NCoA-1 are modiﬁed by dynamic phos-
phorylation and dephosphorylation.
NCoA-1 but not STAT6 hyperphosphorylation inhibits
STAT6/NCoA-1 interaction
So far our results indicate that both STAT6 and NCoA-1
are modiﬁed by phosphorylation. We wondered whether
the modiﬁcation of STAT6 or NCoA-1 or the modiﬁca-
tion of both proteins regulates their interaction. To
address this, we performed GST pull-down experiments
with bait proteins containing the different minimal inter-
action domains. The prey proteins were derived from
extracts of inhibitor treated cells (experimental design
shown in Figure 3D). GST fusion proteins possessing
the STAT6 transactivation domain (GST-STAT6 TAD)
or the NCoA-1 PAS domain (GST-NCoA-1 PAS) were
incubated with lysates from Ramos B cells treated with
IL-4, calyculin A or calyculin A in the presence of
staurosporine. The binding of the interacting partner
protein was analyzed by western blotting with speciﬁc
Figure 2. Phosphatase inhibition induces STAT6 and NCoA-1
phosphorylation. (A) Ocadaic acid and calyculin A-dependent
electromobility shift of STAT6 and NCoA-1. A549, Ramos and THP-1
cells were treated with 2 or 10nM Ocadaic acid (OA) and calyculin A (Ca)
for 2h. Cells were lysed and electromobility of NCoA-1 and STAT6 were
analyzed by SDS–PAGE and western blotting with NCoA-1 and STAT6
speciﬁc antibodies. (B) Phosphorylation of STAT6 and NCoA-1. 2 10
7
BJAB cells were metabolically labeled with 0.5mCi P
32. Cells were treated
for 2h with IL-4 (10ng/ml); calyculin A (10nM) alone or in combination;
or with calyculin A after 30min pretreatment with staurosporine
(200nM). STAT6 and NCoA-1 were immunoprecipitated and phosphor-
ylation of the proteins was analyzed after SDS–PAGE by autoradiog-
raphy. The immunoprecipitation was controlled in parallel by western
blotting with speciﬁc antibodies (lower lane in both panels).
Figure 1. Signaling pathways regulating STAT6/NCoA-1 interaction.
293T cells were transiently transfected with expression vectors
encoding EGFP-STAT6 (100ng) and hNCoA-1 (500ng). Cells were
treated with IL-4 (10ng/ml) 24h after transfection, kinase inhibitors
PD98059 (PD, 50mM), SB202190 (SB, 10mM), SP600125 (SP,
200nM), Staurosporin (St, 200nM) or with the phosphatase inhibitor
calyculin A (Ca, 10nM) as indicated for 2h. Cell extracts were
prepared and co-immunoprecipitation (IP) was performed with an
anti-GFP antibody (GFP), or an unspeciﬁc antibody (IgG). STAT6
bound NCoA-1 was analyzed by SDS–PAGE and western blotting
with an anti-NCoA-1 antibody (left panel). Efﬁciency of the precipita-
tion of GFP-STAT6 was proved by a GFP-speciﬁc antibody (right
panel). As a control two percent of the cell lysates were analyzed in
parallel (In).
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(Figure 3A and B).
No effect on the interaction was observed when extracts
of the treated cells were incubated with GST-NCoA-1
PAS protein (Figure 3A). However, calyculin A treatment
abolished the interaction of cellular NCoA-1 with
GST-STAT6 TAD (Figure 3B). The in vitro interaction
of NCoA-1 with the estrogen receptor (GST-ER E/F)
was not affected or even slightly enhanced by the treat-
ment, thus excluding unspeciﬁc inhibition by degradation
of the cell extract. This result clearly shows that phosphor-
ylation of NCoA-1, but not that of STAT6 abolishes the
interaction (Figure 3D). Therefore active phosphatases are
required to sustain the interaction potential of NCoA-1.
The inhibitory effect of the phosphatase inhibitor was
rescued by kinase inhibitor treatment, hence supporting
that the interaction of NCoA-1 with STAT6 is regulated
by phosphorylation. IL-4 treatment had no signiﬁcant
effect on the STAT6/NCoA interaction regardless of
what direction was analyzed. Our observation, that the
inhibitory effect of calyculin A on the STAT6/NCoA-1
interaction can be reverted was conﬁrmed in coimmuno-
precipitation experiments at the level of the endogenous
proteins (Figure 3C).
PP2A dephosphorylates NCoA-1 and regulates the
interaction of STAT6 and NCoA-1
Calyculin A inhibits the phosphatases PP1 and PP2A at
low concentration (28). Both phosphatases have been
described to regulate the function of NCoA-3 (29).
Inhibition experiments with tautomycin, which at low
concentration selectively inhibits PP1, but PP2A did not
affect the STAT6/NCoA-1 interaction (data not shown).
This indicates that PP1 does not dephosphorylate the
critical NCoA-1 sites. In order to ﬁnd out if PP2A is
involved in the regulation of the STAT6/NCoA-1 inter-
action, we ﬁrst analyzed whether NCoA-1 is a substrate
of PP2A. For this, the PP2A catalytic subunit was
precipitated from cell extract and incubated with P
32
labeled NCoA-1 from extracts of metabolically labeled
cells. NCoA-1 phosphorylation state was determined
after speciﬁc precipitation by SDS–PAGE and autoradi-
ography. To inhibit cellular phosphatases, cells were
treated with calyculin A during labeling. In addition,
calyculin A was included in one reaction (Figure 4A,
last lane) to determine the speciﬁcity of the reaction.
The experiments were performed with substrate derived
from NCoA-1 over expressing 293T cells (left panel),
but also with endogenous NCoA-1 from BJAB cells as
substrate (right panel).
Phosphatase activity was efﬁciently precipitated from
both cell lines with speciﬁc antibodies against the catalytic
domain of PP2A, but not with the control IgG (Figure 4A,
lower panel). Incubation of the precipitated PP2A
holoenzyme with extract from labeled cells resulted in
a decreased amount of radioactive labeled NCoA-1
(Figure 4, upper panel). The dephosphorylation of
NCoA-1 was inhibited when calyculin A was included in
the reaction (last lane). Thus PP2A holoenzyme recovered
from different cell extracts is able to dephosphorylate
Figure 3. NCoA-1 dephosphorylation is essential for its interaction with STAT6. (A and B) Ramos B cells were stimulated with IL-4 (10ng/ml) or
treated with calyculin A (10nM) or with calyculin A in combination with staurosporine (200nM) for 2h. Cells were lysed in NETN buffer and
interaction of endogenous proteins were analyzed in GST pull-down experiments with coupled fusion proteins expressing the PAS domain of
NCoA-1, GST-NCoA-1 Pas (A) or the transactivation domain of STAT6, GST-STAT6-TAD (B) or the activation domain 2 of the estrogen
receptor, GST-ER E/F. Interaction of STAT6 (A) and NCoA-1 (B) was analyzed by western blotting with speciﬁc antibodies. (C) Treatment
of the cells as in A. STAT6 was immunoprecipitated and co-percipitated NCoA-1 was detected after western blotting with speciﬁc antibodies.
The efﬁciency of the STAT6 precipitation was examinated by reprobing with a STAT6 speciﬁc antibody. The amount of NCoA-1 in two percent
of the cell lysates was analyzed in parallel (In). (D) Schematic model of the design and the results of the pull-down experiments performed in (A) (left
panel) and in (B) (right panel).
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strate of PP2A. To further conﬁrm the relationship
between PP2A and its substrate NCoA-1, we investigated
whether NCoA proteins can interact with PP2A. Co-
immunoprecipitation experiments clearly showed that en-
dogenous NCoA-1 and NCoA-3, but not NCoA-2 were
able to bind to the catalytic domain of PP2A (Figure 4B).
Efﬁciency of the precipitation is shown in (Supplementary
Figure S1). Pull-down experiments with GST fusion
proteins containing the catalytic subunit (GST-PP2A/C)
or the scaffold A subunit (GST-PP2A/A) of PP2A con-
ﬁrmed that both NCoA-1 and  3 speciﬁcally interacted
with the catalytic subunit of PP2A (Figure 4C). Our
results coroborated the original ﬁnding that NCoA-3 is
a target of PP2A (29) and extended the function of
PP2A to the regulation of the co-activator NCoA-1.
To prove the signiﬁcance of the PP2A-mediated
dephosphorylation of NCoA-1 for its interaction with
STAT6, binding studies were performed with cells in
which PP2A had been knocked down by siRNA transfec-
tion (Supplementary Figure S2). PP2A depletion by
two different siRNAs strongly inhibited the interaction
of NCoA-1 and STAT6 in co-immunoprecipitation
(Figure 5A) and GST pull-down experiments (Figure 5B).
The interaction was not affected when extract from cells
transfected with control siRNA (scr) were used. The inhibi-
tory effect of PP2A knock down was as efﬁcient as the
phosphatase inhibitor treatment of the cells. Hence,
PP2A-mediated dephosphorylation is the essential regula-
tory mechanism of the STAT6/NCoA-1 interaction.
Phosphatase activity is essential for IL-4 induced
transcriptional activation
To investigate the biological importance of the NCoA-1
dephosphorylation, we analyzed the effect of phosphatase
inhibition and PP2A knockdown on IL-4 induced tran-
scriptional activation. Both okadaic acid and calyculin A
inhibited the IL-4 induced transcription of an STAT6
luciferase reporter construct in a dose-dependent manner
(Figure 6A, upper panel). In contrast, to this an enhance-
ment of the activity of an estrogen responsive reporter was
observed at low-inhibitor concentration (Figure 6A, lower
panel). At high concentration, the estrogen-activated tran-
scription was only slightly inhibited. These results support
that dephosphorylation of NCoA-1 is essential for
STAT6-mediated transcriptional activation, but is a dis-
advantage for the transcriptional activation by the
estrogen receptor. This is in concordance with our
ﬁnding that inhibition of phosphatases has a speciﬁc in-
hibitory effect on the STAT6/NCoA-1 interaction but
slightly enhances the ER/NCoA-1 interaction (Figure 3B).
It has been described that high concentration of
calyculin A (80nM) affects the DNA-binding of STAT6
(23). To rule out that impaired STAT6 DNA-binding
Figure 4. NCoA-1 is dephosphorylated by PP2A. (A) Dephosphorylation of NCoA-1 by PP2A. 293T cells transfected with 3mg of NCoA-1
expression vector were metabolically labeled 24h after transfection with 0.5mCi P
32. Endogenous phosphatases were inactivated prior lysis by
treatment with calyculin A (10nM) for 10min. For the labeling of BJAB cells, 6 10
7 cells were used. For the dephosphorylation assay PP2A
immunoprecipitated out of unlabeled cells was used. As controls, a precipitation with an unspeciﬁc antibody (second lane) and a precipitation of
PP2A under treatment with calyculin A (10nM) (last lane) were used. The dephosphorylation reaction was carried out for 1h at 37 C under shaking.
NCoA-1 was immunoprecipitated out of the lysates and phosphorylation was visualized in autoradiography after SDS–PAGE (upper lanes). The
amount of NCoA-1 was determined by western blotting (lower lanes). The phosphatase activity of the immunoprecipitated PP2A was determined in
parallel (bar chart). (B) Interaction of PP2A with the NCoA family members. Endogenous NCoA-1, NCoA-2 and NCoA-3 were immunoprecipitated
from BJAB cells by speciﬁc antibodies against the different NCoAs (NC). Coprecipitated PP2A was detected by western blotting with an antibody
against the catalytic subunit of PP2A. As controls two percent of the cell lysates were analyzed in parallel (In) and unspeciﬁc binding was analyzed
by precipitation with IgG. (C) Interaction of NCoA proteins with the A and C subunits of PP2A. Lysates of BJAB cells were incubated with
coupeled GST-fusion proteins expressing the A subunit of PP2A (labeled A) or the C subunit of PP2A (labeled C) or with GST as control. Bound
NCoA proteins were detected by western blotting with speciﬁc antibodies.
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we assessed the DNA-binding activity of STAT6 in the
calyculin A treated cells by electrophoretic mobility shift
assay (Supplementary Figure S3A). STAT6 DNA binding
was not affected at the concentration that we used in our
reporter-gene assays. We could also exclude an effect of
calyculin A treatment on the tyrosine phosphorylation
or stability of STAT6 (Supplementary Figure 3B). The
phosphorylation of the C-terminal domain of RNA poly-
merase II was enhanced by treatment with phosphatase
inhibitors, which should have even a positive effect
on general transcription (Supplementary Figure 3C).
All these experiments conﬁrmed our hypothesis that
inhibition of the NCoA-1 dephosphorylation disturbs
its interaction with STAT6 and thereby decreases
STAT6-mediated transcriptional activation.
To conﬁrm the speciﬁc function of PP2A in transcrip-
tional activation in response to IL-4, we analyzed the
effect of PP2A over expression and knockdown in
luciferase reporter-gene assays. The amount of PP2A in
cells transiently transfected with expression-vector coding
for the catalytic domain of PP2A or with PP2A speciﬁc
siRNA was analyzed by western blotting (Supplementary
Figure S4). Overexpression of PP2A resulted in 2-fold
increase of the IL-4 stimulated activity of the STAT6-
reporter construct (Figure 6B). Transfection of the PP2A
speciﬁc siRNA reduced the reporter activity by 50%.
Although treatment with the phosphatase inhibitors
okadaic acid and calyculin A had a much stronger effect
on transcriptional activation, we propose inhibition of
NCoA-1 dephosphorylation as the major factor for the
inhibition of IL-4 activated transcription. This is sup-
ported by the observation that 50% reduction of PP2A
or NCoA-1 by siRNA resulted in comparable reporter
gene activity (Supplementary Figure 5).
Moreover, we analyzed the importance of PP2A for the
induction of endogenous IL-4 target genes. For this,
Ramos cells were transfected with siRNA against PP2A
or as a control with scrambled (scr) siRNA. The RNA
amount of the IL-4 responsive genes Ig epsilon and
TARC was measured in response to IL-4 treatment.
PP2A-protein level and the tyrosine phosphorylation
of STAT6 were determined by western blotting
(Supplementary Figure 6). Strong induction of both
STAT6 target genes was detected after IL-4 treatment of
the cells. This induction was inhibited by PP2A depletion
(Figure 6C). The inhibitory effect on target-gene expres-
sion by PP2A siRNAs was comparable to the inhibition
by low amounts (2nM) of calyculin A. In summary, our
results conﬁrmed that PP2A is an essential regulator
for IL-4 induced gene expression.
Interaction of STAT6 and NCoA-1 is inversely regulated
by phosphatases and cell cycle-dependent kinases
Our previous results indicate that the phosphorylation
status of NCoA-1 is dynamically regulated and that
dephosphorylation is required for binding to STAT6 as
well as for STAT6-mediated transcriptional regulation
(Figures 2B and 3). Short-term treatment of cells with
IL-4 did not affect the STAT6/NCoA-1 interaction
(Figures 1 and 3). However, we observed a slightly
increased nuclear localization of PP2A after 8h IL-4 treat-
ment (Supplementary Figure S7). In order to further char-
acterize the mechanism how NCoA-1 phosphorylation is
regulated in cells, we analyzed which kinase pathway is
responsible for NCoA-1 phosphorylation. 293T cells
transfected with NCoA-1 were metabolically labeled in
the presence of speciﬁc kinase inhibitors. Okadaic acid
and calyculin A treatment strongly enhanced the phos-
phorylation level of NCoA-1 (Figure 7A, upper panel)
and thus conﬁrmed our experiments in the B cell line
(Figure 2B). In contrast, none of the kinase inhibitors
had an effect on the NCoA-1 phosphorylation level,
when applied alone. However, when roscovitine, a
chemical inhibitor of cdk2, cdk1 and cdk5 (30) was
applied in combination with calyculin A, the phosphoryl-
ation of NCoA-1 was dramatically decreased, even
stronger than by staurosporine (Figure 7A, lower panel).
We next tested if roscovitine can also rescue the STAT6/
NCoA-1 interaction when cells were treated with calyculin
A. Both pull-down GST (Figure 7B, lower panel) and co-
immunoprecipitation experiments in Ramos cells
Figure 5. PP2A regulates the STAT6/ NCoA-1 interaction. (A) PP2A-dependent co-precipitation of NCoA-1 with STAT6. 293T cells transfected
with 10nM of two different siRNA against PP2A (siPP2A 1, siPP2A 2) or with an unspeciﬁc siRNA (scr) were transiently transfected 24h later with
plasmids encoding EGFP-STAT6 (1mg) and NCoA-1 (2mg) per 10-cm dish. One sample (scr+Ca) transfected with unspeciﬁc siRNA was treated
with calyculin A (10nM) for 2h. Twenty-four hour later cells were lysed and STAT6 was precipitated by a GFP speciﬁc antibody. Bound NCoA-1
was detected after western blotting with speciﬁc antibody. Efﬁcient precipitation of STAT6 was proven with a GFP speciﬁc antibody. As a control
2% of the cell lysates were analyzed in parallel (In). (B) PP2A-dependent interaction of NCoA-1 with STAT6 in pull-down experiments. Lysates of
293T cells transfected with speciﬁc or unspeciﬁc siRNAs as described in A were incubated with coupeled GST-STAT6-TAD fusion proteins or with
GST as control. Bound NCoA-1 was detected after western blotting with speciﬁc antibody. As a control 10% of the cell lysates were analyzed in
parallel (In).
Nucleic Acids Research,2011, Vol.39, No. 8 3261(Figure 7C) showed that roscovitine treatment can restore
the interaction potential of NCoA-1. Treatment with
roscovitine alone had no effect on the interaction of
NCoA-1 with STAT6 or the estrogen receptor as
determined in GST pull-down experiments (Figure 7B,
upper panel).
It is already known that IL-4 promotes the proliferation
of T lymphocytes by down regulation of p27Kip1 (31).
Figure 6. PP2A regulates transcriptional activation by STAT6. (A) 293T cells were transiently transfected with a STAT6 reporter plasmid and
expression plasmids for STAT6, b-galactosidase for normalization and GFP as transfection control. For the investigation of the estrogen receptor
(ER) regulated transcription, cells were transfected with an ER reporter plasmid and expression plasmids for ER and the control plasmids for
b-galactosidase and GFP. The cells were stimulated with IL-4 for 8h or estrogen over night and treated with different concentrations of phosphatase
inhibitors ocadaic acid (OA) and calyculin A (Ca). Cells were harvested and luciferase and b-galactosidase activities were determinated. The relatve
luciferase activity was normalized to b-galactosidase. (B) 293T cells were transfected with unspeciﬁc or different siRNAs (10nM) against PP2A or an
expression vector encoding for HA-PP2A (50ng) in addition to the STAT6 reporter and expression plasmids. One day later, the cells were stimulated
with IL-4 and treated with 10nM ocadaic acid (OA) or calyculin A (Ca) when indicated. Cells were harvested and luciferase and b-galactosidase
activities were measured. (C) Ramos B cells were transfected with an unspeciﬁc siRNA or different siRNAs against PP2A (40nM) by electroporation.
Forty-eight hour post-transfection, the medium was changed to medium containing 1% FCS. After 8h, the cells were stimulated with IL-4 for 24h.
One sample transfected with unspeciﬁc siRNA was treated in combination with calyculin A (2nM). Total RNA was extracted and the expression
level of Ig-epsilon and TARC were analyzed and normalized against 18S RNA. The results shown in (A), (B) and (C) are the average of three
biological independent experiments.
3262 Nucleic Acids Research, 2011,Vol.39, No. 8It has also been described that NCoA-1 (SRC-1) is
phosphorylated by cyclinA/cdk2 and that this is essential
for its interaction with the progesterone receptor and for
progesterone-dependent activation of target genes (32),
indicating a cell cycle-dependent regulation of NCoA-1
by phosphorylation. We therefore analyzed whether the
phosphorylation of NCoA-1 and its interaction with
STAT6 is regulated during the cell cycle. Cell-cycle
proﬁles of arrested cells were determined by FACS
analysis (Supplementary Figure S8). Enhanced NCoA-1
phosphorylation was observed when cells are arrested at
G1 and S phase, but not at G2 phase (Figure 7D).
NCoA-1 derived from extracts of cells arrested at
distinct phases of the cell cycle was able to bind to
GST-STAT6 fusion proteins (Figure 7E). However, the
inhibition of the STAT6/NCoA-1 interaction by calyculin
A was prevented if cells were arrested at the G2 phase by
colcemide (Figure 7F). These experiments indicate that the
interaction of NCoA-1/STAT6 is regulated by kinases
which are active at G1/S phase. Inactivation of these
Figure 7. NCoA-1 phosphorylation and its interaction potential for STAT6 is regulated by phosphatases and cell cycle-dependent kinases in an
opposite direction. (A) Phosphorylation: 293T cells transiently transfected with NCoA-1 expression plasmids were metabolically labeled one day later
in the presence of different inhibitors: Ocadaic acid (OA, 10nM), calyculin A (Ca, 10nM), PD98059 (PD, 50mM), Roscovitin (Ros, 3mM), SB202190
(SB, 10mM), SP600125 (SP, 200nM) and Staurosporin (St, 200nM) for 2h (upper panel). Cell labeling was also performed after 30min pretreatment
with calyculin A under combined treatment with calyculin A and different kinase inhibitors (lower panel). NCoA-1 was immunoprecipitated and the
protein phosphorylation was determined by autoradiography. Immunoprecipitation was controlled by western blotting with an NCoA-1 speciﬁc
antibody (lower lanes of both panels). (B) GST pull down: lysates of 293T cells treated with inhibitors as in (A) were incubated with
GST-STAT6-TAD or with GST. Bound NCoA-1 was detected by western blotting. Ten percent of the cell lysates were analyzed in parallel as
control (Input). (C) Co-immunoprecipitation: Ramos cells were treated with ocadaic acid (OA, 10nM), calyculin A (Ca, 10nM) or with calyculin A
in combination with roscovitine (Ro, 3mM) after 30min pretreatment. STAT6 was precipitated out of the lysates and coprecipitated NCoA-1 was
detected by western blotting. As a control 2% of the cell lysates were analyzed in parallel (Input). (D) 293T transiently transfected with NCoA-1
expression plasmids (1mg) were arrested at different points of the cell cycle by overnight inhibitor treatment: late G1/S—double thymidine block
(1mM); early G1/S—hydroxyurea (0.5mM) and G2—colcemide (100nM). The cells were metabolically labeled with 0.1mCi P
32 and NCoA-1 was
immunoprecipitated using an NCoA-1 speciﬁc antibody. Phosphorylation was detected by autoradiography (left panel, upper lane).
Immunoprecipitation was controlled by western blotting (left panel, lower lanes). (E) For interaction assays cell lysates derived from cell cycle
arrested 293T cells were incubated with GST or the GST-STAT6-TAD, bound NCoA-1 was detected by western blotting. As a control 10% of the
cell lysates were analyzed in parallel (Input). One probe was derived from non arrested cells treated with calyculin A (10nM) for 2h for comparison
(right lane). (F) To analyze if cell-cycle arrest can affect the inhibition of the NCoA-1/STAT6 interaction by calyculin A, cell-cycle arrested 293T cells
were treated with calyculin A (10nM) 2h before lysate preparation and interaction assay.
Nucleic Acids Research,2011, Vol.39, No. 8 3263kinases by roscovitine treatment or by G2 arrest reconsti-
tutes interaction under conditions where phosphatases are
inhibited. Hence, our results support a dynamic regulation
of the NCoA-1 phosphorylation in which the phosphatase
PP2A is the dominant regulator.
DISCUSSION
The potential importance of serine/threonine phosphoryl-
ation pathways in IL-4 induced transcriptional regulation
has been suggested, but the actual regulators and target
proteins are still largely unknown. We demonstrated here
that the function of NCoA-1 to act as a co-activator of
STAT6 is regulated by serine/threonine phosphorylation.
Dephosphorylation of NCoA-1 by PP2A is essential for
its speciﬁc interaction with STAT6. Regulated phosphor-
ylation and dephosphorylation of NCoA-1 might enable
interactions of NCoA-1 with distinct transcription factors.
Co-activators can thus function as integrators, which co-
ordinate transcriptional regulation by different signaling
pathways (17). The interaction of NCoA-1 with the pro-
gesterone receptor e.g. requires NCoA-1 phosphorylation
(32). In accordance with this we observed a slight enhance-
ment of the NCoA-1 interaction with the estrogen
receptor, another member of the nuclear receptor family
when NCoA-1 dephosphorylation is inhibited (Figure 3B).
Functional regulation by phosphatases has only been
described for NCoA-3 (SRC-3). However, in that study,
PP1 and PP2A affect the transcriptional co-regulatory
activity in steroid receptor-signaling negatively (29).
Our studies revealed that IL-4 induced transcriptional
activation is regulated at an additional level by NCoA-1
phosphorylation. It has been postulated that signal-
induced gene regulation by IL-4 requires serine phosphor-
ylation pathways in addition to the JAK kinase-mediated
tyrosine phosphorylation of STAT6. Both direct and
indirect mechanisms for this regulation have been
described. IL-4 and IL-13 induce phosphorylation of
distinct serine and threonine residues in the transactiva-
tion domain of STAT6 (19), (21), and this can result in an
inhibition of the STAT6 DNA binding (22). Activation of
p38 MAPK by CD40 stimulation enhances transcriptional
activation by STAT6 without affecting STAT6 phosphor-
ylation (20). Although the mechanism for this is still
unclear, it was suggested that p38 MAPK-mediated phos-
phorylation somehow regulates the interaction of STAT6
with co-regulators. Induced phosphorylation of the RNA
Polymerase II C-terminal domain has also been proposed
as a mechanism how serine kinases can modify IL-4-
dependent gene regulation (18). Although we observed a
slightly enhanced serine phosphorylation of STAT6 in
response to IL-4 stimulation (Figure 2B), this had no
effect on the interaction of STAT6 with NCoA-1. In
addition, different serine/threonine kinase pathways
described to modulate IL-4 signaling are obviously not
involved in the regulation of the STAT6/NCoA-1 inter-
action (Figure 1). Hence, the regulation of the STAT6/
NCoA-1 interaction seems not to be involved in the
formerly described examples where IL-4 induced
transcriptional activation are regulated by serine/threo-
nine phosphorylation (18,19,21,22).
We identiﬁed a phosphatase pathway and speciﬁcally
PP2A as the major regulator of the STAT6/NCoA-1
interaction, which is also important for IL-4 responsive
transcriptional activation. PP2A has already been
described to catalyze the dephosphorylation of STAT6
and thereby regulate the DNA binding of STAT6 (23).
However in this work, extremely high concentrations of
the PP1/PP2A inhibitor calyculin A were used (80nM). At
such concentration, PP1 is mainly inhibited. We did not
observe an inhibition of the STAT6/NCoA-1 interaction
by using tautomycin a more speciﬁc PP1 inhibitor
(data not shown). However, we detect an enhanced phos-
phorylation of both STAT6 and NCoA-1 by using much
lower concentration of the inhibitor calyculin A (10nM)
(Figure 2B). At that concentration, no inhibitory effect on
the STAT6 DNA binding could be observed. We therefore
postulate that the reduction of the IL-4 induced gene ex-
pression by PP2A inhibition does not result from the in-
hibition of the STAT6 DNA-binding activity but from the
inhibition of the STAT6/NCoA-1 interaction which does
not take place when NCoA-1 dephosphorylation is in-
hibited. In addition, it has been described that PP2A
directly regulates the activity of the JAK/STAT pathway
by affecting Janus kinases (33,34). However, since we did
not observe an effect on STAT6 tyrosine phosphorylation
either at low-inhibitor concentration (Supplementary
Figure S3) or by PP2A knockdown (Supplementary
Figure S6), such a mechanism could be ruled out in the
case of IL-4-mediated gene regulation. Until now, we
cannot exclude that desphosphorylation of other
coactivators or co-activator multiprotein complex forma-
tion are also regulated by PP2A-mediated dephosphory-
lation. This has to be analyzed in further studies.
The phosphorylation of both STAT6 and NCoA-1
is enhanced when PP2A is inhibited by calyculin A.
Our results indicate that only the phosphorylation of
NCoA-1 is essential for the regulation of the STAT6/
NCoA-1 interaction. This is in agreement with the
ﬁnding that IL-4 treatment which slightly enhances
STAT6 phosphorylation, but not NCoA-1 phosphoryl-
ation does not affect the STAT6/NCoA-1 interaction
either. Transcriptional regulation requires the speciﬁc
interaction of transcription factors and co-activators.
The members of NCoA co-activator family are involved
in transcriptional activation by several transcription
factors, which are themselves controlled by distinct signal-
ing pathways. Several studies already showed that NCoA
proteins are post-translationally modiﬁed and that such
modiﬁcations can disturb protein interaction and
regulate the cellular localization, stability and conform-
ation of NCoA proteins (15). In the case of NCoA-3,
the best studied family member, a phosphorylation-
dependent mono- and polyubiquitination has been
identiﬁed, which is essential for transcriptional regulation
by nuclear hormone receptors and regulates co-activator
degradation during the transcriptional activation process
(35). The retarded electrophoretic mobility of NCoA-1
that we detected after calyculin A treatment could also
be caused by mono-ubiquitination. However, we did not
3264 Nucleic Acids Research, 2011,Vol.39, No. 8detect an enhanced degradation of NCoA-1 after calyculin
A treatment (Figure 2) or by knockdown of PP2A
(Supplementary Figure S4). In preliminary experiments,
we could also not detect enhanced ubiquitination or
sumoylation (data not shown).
Although the phosphorylation of NCoA-1 is not
regulated in response to short-term IL-4 stimulation our
results advise to a dynamic phosphorylation and dephos-
phorylation process, whereas the dephosphorylation by
PP2A seems to be stronger. This is corroborated by the
ﬁnding that sole inhibition of kinases by staurosporin or
roscovitine had no signiﬁcant effect on the NCoA-1 phos-
phorylation or its interaction with STAT6. Only simultan-
eous inhibition of kinases and phosphatases shows a
signiﬁcant effect (Figure 7). Kinases active during G1/S
phase obviously mediate NCoA-1 phosphorylation and
thereby regulate its co-activator function for STAT6
(Figure 7). Other kinase described to be involved in IL-4
signaling do not play a role in this process. It is already
known that IL-4 alone or in combination with CD40
stimulation promotes the proliferation of lymphocytes
by upregulation of cyclin D3 and cdk6 and down regula-
tion of p27 (31,36). Cdk2 which is active during G1/S has
been described to phosphorylate NCoA-1 and thereby
enhances its co-activator function for progesterone
receptor (32). Our ﬁnding indicates that phosphorylation
by cdk2 also impedes the co-activator function of NCoA-1
for STAT6. We would therefore expect that IL-4 can
further modulate transcriptional regulation by altering
the phosphorylation state of NCoA-1 via regulating
cycle-dependent kinase activity. Several examples for
cell-cycle-dependent regulation of nuclear hormone
receptor-driven transcriptional activation had already
been described (37). Different mechanisms are involved
including the function of cyclins as bridging factors. A
recruitment of cyclin D1 by a STAT3/NCoA complex
which prevents the recruitment of CBP and RNA poly-
merase II has also been described (38). The function of
cyclins in STAT6-mediated gene regulation has to be
determined in future experiments. It will also be important
to investigate if transcriptional activation by STAT6 is
modulated by cell cycle. Such a regulation could be im-
portant in fast proliferating cells like leukemia cells which
have a different cell-cycle status.
Our results show an essential function of PP2A in
STAT6 regulated transcriptional activation. PP2A
dephophorylates NCoA-1 and thereby regulates its inter-
action potential with STAT6 as shown in the model in
Figure 8. Cdk2 phosphorylates NCoA-1, when it is
active during the cell cycle. It is not yet clear how the
activity of PP2A is regulated in this process. Our prelim-
inary experiments indicate that long-term IL-4 treatment
enhances a transient localization of PP2A into the nucleus
(Supplementary Figure 7). The amount of PP2A that can
dephosphorylate nuclear NCoA-1 can thus be regulated
by IL-4. However, we expect that speciﬁc regulatory
subunits of PP2A will have an even more important
function in controlling the PP2A activity. Although we
detected a direct interaction of NCoA-1 with the catalytic
subunit of PP2A in vitro (Figure 4C) regulatory subunits
of PP2A will be essential for its regulation in the cellular
context (39). Our results point to an additional level of
regulation for STAT6-activated genes by co-activator
phosphorylation. This may have an important function
in speciﬁc cell types in the context of the activated
signaling pathways and transcription factors and can
have therapeutic impact.
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